Spotlight: France: What the President Must do for Biotech
Entrepreneur Philippe Pouletty, president of France Biotech, spells out to In Vivo Europe what's holding France's industry back, and what newly elected President Jacques Chirac needs to do about it.
You may also be interested in...
The French government's efforts to encourage biotechnology have been modest and somewhat piecemeal. Yet two years ago, France's industry was nevertheless ranked second in Europe. Since then, the explosion of biotech companies in Germany, along with steady growth in other European markets, make the need for a coherent French strategy more urgent. France needs to take some bolder, more generous measures--particularly to reduce companies' tax burden and attract talent from overseas--without which it risks restricting itself to a small group of companies, many of whom will have to move elsewhere to grow substantially.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.